TKI Hikes Survival in Recurrent Ovarian CancerTKI Hikes Survival in Recurrent Ovarian Cancer

Cediranib, bevacizumab, and novel antiangiogenic agents continue to improve survival in first-line and recurrent ovarian cancer, as reported by Dr. Stanley Kaye from ECC 2013. Medscape Oncology

Source: Medscape Today Headlines - October 4, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news